X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

NRXPW

Closed

Nrx Pharmaceuticals Inc

0.0851
0.0000 (0.00%)
Last Update: 30 Jun 2025 23:00:00
Yesterday: 0.0851
Day's Range: 0.0851 - 0.1
Send
When Written:
 
0.1626
NRx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for neurological and psychiatric disorders. The company was founded in 2015 and is headquartered in New York City. NRx Pharmaceuticals is led by Dr. Jonathan Javitt, a physician-scientist with more than 30 years of experience in the pharmaceutical industry.

NRx Pharmaceuticals is focused on developing therapies for conditions such as depression, anxiety, and schizophrenia. The company's lead product candidate is NRX-101, a nasal spray formulation of ketamine, which is being developed for the treatment of suicidal ideation and major depressive disorder. NRx Pharmaceuticals is also developing NRX-102, a long-acting oral formulation of ketamine, for the treatment of bipolar depression and post-traumatic stress disorder.

NRx Pharmaceuticals has received funding from a number of sources, including private investors, venture capital firms, and government grants. The company has also formed partnerships with other pharmaceutical companies to develop and commercialize its products.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X